TrialSite News: “Pharma Drama: bluebird bio, Inc. Directors Accused of “Grossly Excessive” Compensation While Separate Errant Gene Therapeutics Lawsuit Heads for Trial

In new twists on a convoluted tale of medicine and money, a shareholder lawsuit against bluebird bio, Inc.’s (formerly Genetix) directors is accusing them of overpaying themselves, as other litigation moves forward. bluebird bio has been featured on our site in the past; a good overview of the ongoing battle of Errant Gene Therapeutics (EGT) versus bluebird bio, capital firm Third Rock Ventures, and the Memorial Sloan Kettering center (MSK) can be found here. Other news about bluebird partnering with Novo- Nordisk is here. The bluebird-MSK litigation accuses both of essentially slow walking and trying to “kill” EGT’s allegedly superior gene vector product.

Read More at TrialSite News

View PDF